September 24, 2018
Radiation Science Researchers Will Gather In Chicago for the 64th Annual Meeting of the Radiation Research Society
The University of Maryland School of Medicine (UMSOM) announced that the Division of Translational Radiation Science (DTRS) will participate in the annual meeting of the Radiation Research Society (RRS) on September 23-26, 2018, in Chicago.
UMSOM supports the critical objectives of the RRS to advance radiation research in all disciplines of science and medicine, to foster collaboration within a community of radiation scientists, industry-partners, and federal sponsors, and to disseminate knowledge in radiation research to the scientific community and the public. “Our participation in this conference underscores our dedication to the advancement of radiation research, from preclinical science to clinical radiotherapy applications,” said William F. Regine, MD, FACR, FACRO, the Isadore & Fannie Schneider Foxman Chair of the Department of Radiation Oncology at UMSOM. “The research we are sharing will help push the field forward in important ways.”
Exhibiting this year at Booth 6, DTRS will present its expanding portfolio of services in medical countermeasure development and clinically-relevant normal tissue injury, as well as their enhanced GLP compliance program. “At DTRS, we have implemented significant improvement and progress toward meeting the challenges of regulatory compliance, including hiring quality experts, project managers, and technical staff with decades of experience in the pharmaceutical industry and technology-development,” said Dr. Vujaskovic. “The strength of our GLP program lies in the strong support and commitment of the institution.”
Isabel Jackson, PhD, associate professor of radiation oncology and deputy director of DTRS, and Zeljko Vujaskovic, MD, PhD, professor of radiation oncology and director of DTRS, will present four posters focused on models of acute radiation sickness. This work received support from the Biomedical Advanced Research and Development Authority (BARDA), the National Institutes of Allergy and Infectious Diseases (NIAID), and industry partners. “I strongly believe culture starts at the top,” said Dr. Jackson. “The School of Medicine’s Test Facility Management and Quality Assurance Unit are staffed by quality professionals with more than 40 years of experience in the pharmaceutical and contract-manufacturing sectors. The strong institutional commitment to the mission of the DTRS and its federal and industry sponsors is critical to rapid growth of the DTRS and continued assurance that the Division’s GLP quality management system meets industry standards.”
About the University of Maryland School of Medicine
Commemorating its 211th Anniversary, the University of Maryland School of Medicine was chartered in 1807 as the first public medical school in the United States. It continues today as one of the fastest growing, top-tier biomedical research enterprises in the world -- with 43 academic departments, centers, institutes, and programs; and a faculty of more than 3,000 physicians, scientists, and allied health professionals, including members of the National Academy of Medicine and the National Academy of Sciences, and a distinguished recipient of the Albert E. Lasker Award in Medical Research. With an operating budget of more than $1 billion, the School of Medicine works closely in partnership with the University of Maryland Medical Center and Medical System to provide research-intensive, academic and clinically-based care for more than 1.2 million patients each year. The School has over 2,500 students, residents, and fellows, and nearly $520 million in extramural funding, with most of its academic departments highly ranked among all medical schools in the nation in research funding. As one of the seven professional schools that make up the University of Maryland Baltimore campus, the School of Medicine has a total workforce of nearly 7,000 individuals. The combined School and Medical System (“University of Maryland Medicine”) has an annual budget of nearly $6 billion and an economic impact in excess of $15 billion on the state and local community. The School of Medicine faculty, which ranks as the 8th-highest public medical school in research productivity, is an innovator in translational medicine, with 600 active patents and 24 start-up companies. The School works locally, nationally, and globally, with research and treatment facilities in 36 countries around the world. Visit medschool.umaryland.edu/
Contact
Office of Public Affairs
655 West Baltimore Street
Bressler Research Building 14-002
Baltimore, Maryland 21201-1559
Contact Media Relations
(410) 706-5260
Related stories
Monday, February 26, 2024
UM School of Medicine Awarded $3.5 Million in Federal Funding to Expand Medical Countermeasures Program
University of Maryland School of Medicine (UMSOM) Dean Mark T. Gladwin, MD, announced today that UMSOM faculty scientists have been selected as key contractors by the Biomedical Advanced Research and Development Authority (BARDA), for the federal agency’s Radiation Nuclear Animal Model Development program. The $3.5 million award that Erika Davies, PhD, Assistant Professor of Radiation Oncology, received to develop Acute Radiation Syndrome Animal Models, has a $16 million potential total. The Division of Translational Radiation Sciences (DTRS), within the Department of Radiation Oncology, will support this project.
Thursday, March 09, 2023
Leading Physician-Scientist Dr. William F. Regine Named Senior Associate Dean for Clinical Affairs at UM School of Medicine and President of UM Faculty Physicians, Inc.
University of Maryland School of Medicine (UMSOM) Dean Mark T. Gladwin, MD announced today that William F. Regine, MD, FACR, FASTRO, FACRO has been appointed to the executive role of Senior Associate Dean for Clinical Affairs at the University of Maryland School of Medicine (SOM), effective immediately.
Tuesday, December 07, 2021
UM School of Medicine's Department of Radiation Oncology Announces that Preeminent Scientist, Dr. Zeljko Vujaskovic, will Transition to New Role in the Department
University of Maryland School of Medicine (UMSOM) Radiation Oncology Department Chair William F. Regine, MD, FACR, FACRO, announced today that Zeljko Vujaskovic, MD, PhD, Professor and Vice Chair for Research in the Department of Radiation Oncology, will transition from his current faculty position to a new role in the Department, effective December 3, 2021.
Tuesday, August 24, 2021
Three UMSOM Faculty Members Recognized as 2021 Maryland Daily Record Health Care Heroes
The Maryland Daily Record has honored three leading faculty members at the University of Maryland School of Medicine (UMSOM) with its 2021 Health Care Heroes Awards. The award recognizes those who have provided exceptional service and made significant impacts on the quality of health care in the State of Maryland this year. An outside panel of health care experts selected the winners.
Tuesday, November 17, 2020
UMSOM's Department of Radiation Oncology Announces New Endowed Professorship and Senior Leadership Appointments in the Department
University of Maryland School of Medicine (UMSOM) Department of Radiation Oncology Chair William F. Regine, MD, FACR, FACRO, along with UMSOM Dean E. Albert Reece, MD, PhD, MBA, announced today that three prominent faculty members in the Department of Radiation Oncology will be promoted into leading department positions that recognize their outstanding academic scholarship and success.
Friday, October 11, 2019
New Treatment Combination Could Work Against Broader Array of Cancer Cells, Study Finds
In continuing efforts to find novel ways to kill cancer cells, researchers at the University of Maryland School of Medicine (UMSOM) have identified a new pathway that leads to the destruction of cancer cells. The new finding, published this week in the journal PNAS, could pave the way for the broader use of a class of anticancer drugs already on the market. These drugs, known as PARP inhibitors, are currently approved by the FDA to treat only a limited group of breast and ovarian cancers associated with BRCA gene mutations.
Wednesday, July 31, 2019
Inconsistent Reporting of Methodologies Makes Most Radiation Biology Studies Impossible to Replicate
Nearly 80 percent of radiation oncology studies funded by the National Institutes of Health involve investigating the effects that radiation has on tumor cells and healthy tissue in pre-clinical settings, such as experiments done in cell cultures or mice. A majority of these radiation biology studies, however, have serious flaws in how their irradiation methodology is described, which makes them very difficult to replicate, according to a new finding from the University of Maryland School of Medicine (UMSOM).
Tuesday, February 19, 2019
Dr. Robert C. Miller, National Leader in Radiation Oncology, Named New Medical Director of Maryland Proton Treatment Center
William F. Regine, MD, FACR, FACRO, The Isadore and Fannie Schneider Foxman Chair and Professor of Radiation Oncology at the University of Maryland School of Medicine (UMSOM), along with UMSOM Dean E. Albert Reece, MD, PhD, MBA, announced today that Robert C. Miller, MD, MBA, FASTRO a nationally-recognized radiation oncologist who currently serves as Vice Chair in the Department of Radiation Oncology at the Mayo Clinic, has been named Professor in the UMSOM Department of Radiation Oncology and Medical Director of the Maryland Proton Treatment Center (MPTC). He will begin his new position in April 2019.
Monday, October 29, 2018
UMSOM Honors Breast Cancer Awareness Month, Our Research Continues Toward Combating this Disease
October is Breast Cancer Awareness Month, and researchers at the University of Maryland School of Medicine (UMSOM) continue in their work to help combat this disease that impacts more than 315,000 women in the U.S. each year.
Monday, October 08, 2018
High-Precision Proton Therapy More Effective in Treating Certain Cancers When Combined with Thermal Therapy
The Maryland Proton Treatment Center (MPTC) is now offering deep-tissue external thermal therapy in combination with high-precision proton-beam radiotherapy as a potential way to boost survival chances for certain cancer patients. MPTC is the only center in the world to offer these two treatments at the same facility, an advantage to patients because these therapies are typically given within an hour of each other.
Monday, May 14, 2018
Gov. Larry Hogan Recognizes Achievements of Sally B. Cheston, MD, of Central Maryland Radiation Oncology Center
Maryland Gov. Larry Hogan today recognized Sally B. Cheston, MD, an assistant professor of radiation oncology at the University of Maryland School of Medicine (UMSOM), for her efforts to bring the “latest state-of-the-art medicine” to Howard County as a leader of the Central Maryland Radiation Oncology Center (CMRO).
Friday, December 22, 2017
First Stereotactic Radiation Therapy System Designed To Treat Early Stage Breast Cancer Receives FDA Clearance
The GammaPod ™ – a first-of-its kind stereotactic radiotherapy system to treat early stage breast cancer – has received 510(k) clearance from the U.S. Food and Drug Administration (FDA), paving the way for the manufacturer to bring the system to market for the treatment of breast cancer patients.
Wednesday, October 18, 2017
University of Maryland School of Medicine Scientists Set to Begin Critical Radiation Countermeasures Research
University of Maryland School of Medicine (UM SOM) Department of Radiation Oncology Chair and Professor William F. Regine, MD, FACR, FACRO, and UM SOM Dean E. Albert Reece, MD, PhD, MBA, announced today that UM SOM researchers have been awarded a contract worth up to $9.7 million over three years, from the U.S. Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response (ASPR) at the U.S. Department of Health and Human Services to study new ways to treat radiation-induced bleeding disorders. BARDA is part of the Office of the Secretary for Preparedness and Response in the U.S. Department of Health and Human Services.
Thursday, October 27, 2016
Dr. William F. Regine is Awarded 2016 Entrepreneur of the Year From the University of Maryland, Baltimore
William F. Regine, MD, FACR, FACRO, the Isadore & Fannie Schneider Foxman Endowed Chair and Professor in Radiation Oncology at the University of Maryland School of Medicine (UM SOM) and Executive Director of the Maryland Proton Treatment Center (MPTC) has been awarded the 2016 Entrepreneur of the Year from the University of Maryland, Baltimore (UMB).
Thursday, July 14, 2016
Dr. Charles B. Simone, II Appointed Medical Director of the Maryland Proton Treatment Center
William F. Regine, MD, FACR, FACRO, the Isadore & Fannie Foxman Schneider Endowed Chairman and Professor of Radiation Oncology at the University of Maryland School of Medicine (UM SOM) and the Executive Director of the Maryland Proton Treatment Center (MPTC), along with UM SOM Dean E. Albert Reece, MD, PhD, MBA, announced today that Charles B. Simone, II, MD, a nationally-recognized expert in proton therapy at the University of Pennsylvania, has been named the new Medical Director of the MPTC. Dr. Simone will also be appointed Associate Professor in the UM SOM Department of Radiation Oncology and will begin in his new position in November 2016.
Wednesday, April 13, 2016
Leading Physician-Scientist at University of Maryland School of Medicine Receives Award for Innovative Work in Thermal Treatment for Cancer
Zeljko Vujaskovic, MD, PhD, an internationally recognized physician scientist and Professor of Radiation Oncology at the University of Maryland School of Medicine (UM SOM), will receive the 2016 J. Eugene Robinson Award at the annual Society for Thermal Medicine Meeting in New Orleans, held April 11 to 15. Dr. Vujaskovic, who is also Director of the Division of Translational Radiation Sciences in the UM SOM Department of Radiation Oncology, and Director of the Maryland Proton Alliance at UM SOM, will receive the award in recognition of his contributions to hyperthermic oncology, the use of heat to treat cancer. At the event, Dr. Vujaskovic will also present a lecture on the reemerging role of thermal therapy in cancer treatment.
Friday, January 15, 2016
UM SOM to Participate in Expanded Medical Countermeasures Research Project
University of Maryland School of Medicine (UM SOM) Department of Radiation Oncology Chair and Professor William F. Regine, MD, FACR, FACRO, and UM SOM Dean E. Albert Reece, MD, PhD, MBA, announced today that researchers at the UM SOM have been selected as key contractors by the Biomedical Advanced Research and Development Authority (BARDA), for its Radiation Nuclear Animal Model Development program. BARDA is part of the Office of the Secretary for Preparedness and Response in the U.S. Department of Health and Human Services (DHHS).